Primidone

Major

Primidone Metronidazole Topical MetroCream® An increased risk of QT interval prolongation, reduced metroNIDAZOLE exposure and reduced metroNIDAZOLE efficacy Details Primidone Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation, reduced metroNIDAZOLE exposure and reduced metroNIDAZOLE efficacy Details Primidone Miconazole Buccal Oravig Increased PHENobarbital exposure and an increased risk of PHENobarbital-related adverse effects Details Primidone Miconazole Topical Aloe Vesta Antifungal Increased PHENobarbital exposure and an increased risk of PHENobarbital-related adverse effects Details Primidone Miconazole Vaginal Lagicam Increased PHENobarbital exposure and an increased risk of PHENobarbital-related adverse effects Details Primidone Miconazole Aloe Vesta Antifungal Increased PHENobarbital exposure and an increased risk of PHENobarbital-related adverse effects Details Primidone Midazolam Nasal Spray Nayzilam An increased risk of CNS depression, reduced midazolam exposure and reduced efficacy of midazolam Details Primidone Midazolam Injection Nayzilam An increased risk of CNS depression, reduced midazolam exposure and reduced efficacy of midazolam Details Primidone Mitapivat Aqvesme Reduced mitapivat exposure and reduced efficacy of mitapivat Details Primidone Morphine Injection Astramorph® PF Increased risk of profound sedation, respiratory depression, hypotension, coma and death Details Primidone Moxifloxacin Avelox An increased risk of QT interval prolongation Details Primidone Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Primidone Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Primidone Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation Details Primidone Nalbuphine Injection Nubain® Increased risk of respiratory and CNS depression Details Primidone Naldemedine Symproic Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Naloxegol Movantik Reduced naloxegol exposure and reduced efficacy of naloxegol Details Primidone Nateglinide Starlix® Reduced nateglinide exposure and reduced efficacy of nateglinide Details Primidone Neratinib Nerlynx Decreased exposure of neratinib and risk of reduced efficacy Details Primidone Nintedanib Ofev Reduced nintedanib exposure and reduced efficacy of nintedanib Details Primidone Nisoldipine Sular Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Primidone Octreotide Bynfezia An increased risk of QT interval prolongation Details Primidone Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Primidone Ofloxacin Floxin® An increased risk of QT interval prolongation Details Primidone Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Primidone Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Primidone Olaparib Lynparza Decreased olaparib exposure and efficacy Details Primidone Olutasidenib Rezlidhia Reduced olutasidenib exposure Details Primidone Oxaliplatin Injection Eloxatin® An increased risk of QT interval prolongation Details Primidone Orlistat Alli Reduced efficacy of anticonvulsant Details